Tango Therapeutics Inc

{ "date": [ "202612", "202712", "202812", "202912", "203012" ], "revenue_estimate": [ null, null, 62.4, 214.24, 695.47 ], "ebit_estimate": [ -206.74, -257.91, -282.26, -188.47, 240.21 ], "ebitda_estimate": [ -217.61, -306.27, -55.01, -102.08, 231.91 ], "net_income_estimate": [ -194.49, -250.57, -274.77, -181.22, 231.53 ], "per_share_eps_estimate": [ -1.3, -1.54, -1.67, -0.99, 1.16 ], "eps_nri_estimate": [ -1.3, -1.54, -1.67, -0.99, 1.16 ], "dividend_estimate": [ null, null, null, null, null ], "book_value_per_share_estimate": [ null, null, null, null, null ], "pretax_income_estimate": [ -194.49, -250.57, -272.94, -163.74, 245.18 ], "operating_cash_flow_per_share_estimate": [ null, null, null, null, null ], "roa_estimate": [ null, null, null, null, null ], "roe_estimate": [ null, null, null, null, null ], "gross_margin_estimate": [ 100, 100, 96, 90, 90 ], "operating_cash_flow_estimate": [ null, null, null, null, null ], "pettm_estimate": [ 0, 0, 0, 0, 26.75 ], "long_term_growth_rate_mean": -23.75, "long_term_revenue_growth_rate_mean": "0.00", "future_per_share_eps_estimate_growth": -23.75, "future_eps_nri_estimate_growth": -23.75, "future_revenue_estimate_growth": null, "future_ebit_estimate_growth": -35.16, "future_ebitda_estimate_growth": null, "future_dividend_estimate_growth": null, "future_net_income_estimate_growth": -38.24, "future_pretax_income_estimate_growth": -37.96, "future_book_value_per_share_estimate_growth": null, "future_roa_estimate_growth": null, "future_roe_estimate_growth": null, "future_gross_margin_estimate_growth": null, "future_operating_cash_flow_per_share_estimate_growth": null }

{ "date": [ "202606", "202609", "202612", "202703", "202706", "202709", "202712" ], "revenue_estimate": [ null, null, null, null, null, null, null ], "ebit_estimate": [ -50.48, -53.3, -56.11, -56.52, -59.71, -62.61, -65.06 ], "ebitda_estimate": [ -52.54, -56.56, -59.98, -59.67, -67.56, -74.42, -79.5 ], "net_income_estimate": [ -47.17, -49.6, -52.36, -54.67, -58.33, -61.5, -64.04 ], "per_share_eps_estimate": [ -0.32, -0.33, -0.34, -0.34, -0.37, -0.38, -0.39 ], "eps_nri_estimate": [ -0.32, -0.33, -0.34, -0.34, -0.37, -0.38, -0.39 ], "dividend_estimate": [ null, null, null, null, null, null, null ], "book_value_per_share_estimate": [ null, null, null, null, null, null, null ], "pretax_income_estimate": [ -47.17, -49.6, -52.36, -54.67, -58.33, -61.5, -64.04 ], "operating_cash_flow_per_share_estimate": [ null, null, null, null, null, null, null ], "roa_estimate": [ null, null, null, null, null, null, null ], "roe_estimate": [ null, null, null, null, null, null, null ], "gross_margin_estimate": [ 100, 100, 100, null, null, null, null ], "operating_cash_flow_estimate": [ null, null, null, null, null, null, null ], "pettm_estimate": [ 0, 0, 0, 0, null, null, null ], "long_term_growth_rate_mean": -23.75, "long_term_revenue_growth_rate_mean": "0.00", "future_per_share_eps_estimate_growth": -23.75, "future_eps_nri_estimate_growth": -23.75, "future_revenue_estimate_growth": null, "future_ebit_estimate_growth": -35.16, "future_ebitda_estimate_growth": null, "future_dividend_estimate_growth": null, "future_net_income_estimate_growth": -38.24, "future_pretax_income_estimate_growth": -37.96, "future_book_value_per_share_estimate_growth": null, "future_roa_estimate_growth": null, "future_roe_estimate_growth": null, "future_gross_margin_estimate_growth": null, "future_operating_cash_flow_per_share_estimate_growth": null }